I've been watching $JUNS closely, and with the selloff without negative news and strong insider ownership, I believe it could bounce back. The current price feels like a great entry point, especially given their ongoing Phase 2 clinical trials that could lead to significant developments in the future.

I believe JUNS has strong potential for a run due to high short interest, a solid target price from Greenridge Capital, and a low public float that could lead to a significant squeeze. The CEO's acknowledgment of short attacks adds credence to this potential upside.